Cross-disciplinary biomarkers research

Lessons learned by the CKD biomarkers consortium

CKD Biomarkers Consortium

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Significant advances are needed to improve the diagnosis, prognosis, and management of persons with CKD. Discovery of new biomarkers and improvements in currently available biomarkers for CKD hold great promise to achieve these necessary advances. Interest in identification and evaluation of biomarkers for CKD has increased substantially over the past decade. In 2009, the National Institute of Diabetes and Digestive and Kidney Diseases established the CKD Biomarkers Consortium (http://www.ckdbiomarkersconsortium.org/), a multidisciplinary, collaborative study group located at over a dozen academic medical centers. The main objective of the consortium was to evaluate new biomarkers for purposes related to CKD in established prospective cohorts, including those enriched for CKD. During the first 5 years of the consortium, many insights into collaborative biomarker research were gained that may be useful to other investigators involved in biomarkers research. These lessons learned are outlined in this Special Feature and include a wide range of issues related to biospecimen collection, storage, and retrieval, and the internal and external quality assessment of laboratories that performed the assays. The authors propose that investigations involving biomarker discovery and validation are greatly enhanced by establishing and following explicit quality control metrics, including the use of blind replicate and proficiency samples, by carefully considering the conditions under which specimens are collected, handled, and stored, and by conducting pilot and feasibility studies when there are concerns about the condition of the specimens or the accuracy or reproducibility of the assays.

Original languageEnglish (US)
Pages (from-to)894-902
Number of pages9
JournalClinical Journal of the American Society of Nephrology
Volume10
Issue number5
DOIs
StatePublished - Jan 1 2015

Fingerprint

Biomarkers
Research
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
Feasibility Studies
Quality Control
Research Personnel

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Cross-disciplinary biomarkers research : Lessons learned by the CKD biomarkers consortium. / CKD Biomarkers Consortium.

In: Clinical Journal of the American Society of Nephrology, Vol. 10, No. 5, 01.01.2015, p. 894-902.

Research output: Contribution to journalArticle

@article{94ef7b92428d4c4a8c71c28f07a05e0d,
title = "Cross-disciplinary biomarkers research: Lessons learned by the CKD biomarkers consortium",
abstract = "Significant advances are needed to improve the diagnosis, prognosis, and management of persons with CKD. Discovery of new biomarkers and improvements in currently available biomarkers for CKD hold great promise to achieve these necessary advances. Interest in identification and evaluation of biomarkers for CKD has increased substantially over the past decade. In 2009, the National Institute of Diabetes and Digestive and Kidney Diseases established the CKD Biomarkers Consortium (http://www.ckdbiomarkersconsortium.org/), a multidisciplinary, collaborative study group located at over a dozen academic medical centers. The main objective of the consortium was to evaluate new biomarkers for purposes related to CKD in established prospective cohorts, including those enriched for CKD. During the first 5 years of the consortium, many insights into collaborative biomarker research were gained that may be useful to other investigators involved in biomarkers research. These lessons learned are outlined in this Special Feature and include a wide range of issues related to biospecimen collection, storage, and retrieval, and the internal and external quality assessment of laboratories that performed the assays. The authors propose that investigations involving biomarker discovery and validation are greatly enhanced by establishing and following explicit quality control metrics, including the use of blind replicate and proficiency samples, by carefully considering the conditions under which specimens are collected, handled, and stored, and by conducting pilot and feasibility studies when there are concerns about the condition of the specimens or the accuracy or reproducibility of the assays.",
author = "{CKD Biomarkers Consortium} and Hsu, {Chi Yuan} and Shawn Ballard and Daniel Batlle and Bonventre, {Joseph V.} and B{\"o}ttinger, {Erwin P.} and Feldman, {Harold I.} and Klein, {Jon B.} and Josef Coresh and Eckfeldt, {John H.} and Inker, {Lesley A.} and Kimmel, {Paul L.} and Kusek, {John W.} and Liu, {Kathleen D.} and Michael Mauer and Mifflin, {Theodore E.} and Molitch, {Mark E.} and Nelsestuen, {Gary L.} and Rebholz, {Casey M.} and Rovin, {Brad H.} and Sabbisetti, {Venkata S.} and {Van Eyk}, {Jennifer E.} and Vasan, {Ramachandran S.} and Waikar, {Sushrut S.} and Whitehead, {Krista M.} and Nelson, {Robert G.} and Ramachandran, {Vasan S.} and Joseph Bonventre and Sushrut Waikar and Venkata Sabbisetti and {Van Eyk}, Jennifer and Qin Fu and Hermine Brunner and Vivette D’Agati and Jonathan Barasch and Josef Coresh and Rebholz, {Casey M.} and Go, {Alan S.} and Erwin B{\"o}ttinger and Avelino Teixeira and Ilse Daehn and Mark Molitch and Daniel Batlle and Brad Rovin and Haifeng Wu and Levey, {Andrew S.} and Inker, {Lesley A.} and Foster, {Meredith C.} and Hsu, {Chi Yuan} and Kathleen Liu and Bruce Molitoris",
year = "2015",
month = "1",
day = "1",
doi = "10.2215/CJN.11541114",
language = "English (US)",
volume = "10",
pages = "894--902",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Cross-disciplinary biomarkers research

T2 - Lessons learned by the CKD biomarkers consortium

AU - CKD Biomarkers Consortium

AU - Hsu, Chi Yuan

AU - Ballard, Shawn

AU - Batlle, Daniel

AU - Bonventre, Joseph V.

AU - Böttinger, Erwin P.

AU - Feldman, Harold I.

AU - Klein, Jon B.

AU - Coresh, Josef

AU - Eckfeldt, John H.

AU - Inker, Lesley A.

AU - Kimmel, Paul L.

AU - Kusek, John W.

AU - Liu, Kathleen D.

AU - Mauer, Michael

AU - Mifflin, Theodore E.

AU - Molitch, Mark E.

AU - Nelsestuen, Gary L.

AU - Rebholz, Casey M.

AU - Rovin, Brad H.

AU - Sabbisetti, Venkata S.

AU - Van Eyk, Jennifer E.

AU - Vasan, Ramachandran S.

AU - Waikar, Sushrut S.

AU - Whitehead, Krista M.

AU - Nelson, Robert G.

AU - Ramachandran, Vasan S.

AU - Bonventre, Joseph

AU - Waikar, Sushrut

AU - Sabbisetti, Venkata

AU - Van Eyk, Jennifer

AU - Fu, Qin

AU - Brunner, Hermine

AU - D’Agati, Vivette

AU - Barasch, Jonathan

AU - Coresh, Josef

AU - Rebholz, Casey M.

AU - Go, Alan S.

AU - Böttinger, Erwin

AU - Teixeira, Avelino

AU - Daehn, Ilse

AU - Molitch, Mark

AU - Batlle, Daniel

AU - Rovin, Brad

AU - Wu, Haifeng

AU - Levey, Andrew S.

AU - Inker, Lesley A.

AU - Foster, Meredith C.

AU - Hsu, Chi Yuan

AU - Liu, Kathleen

AU - Molitoris, Bruce

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Significant advances are needed to improve the diagnosis, prognosis, and management of persons with CKD. Discovery of new biomarkers and improvements in currently available biomarkers for CKD hold great promise to achieve these necessary advances. Interest in identification and evaluation of biomarkers for CKD has increased substantially over the past decade. In 2009, the National Institute of Diabetes and Digestive and Kidney Diseases established the CKD Biomarkers Consortium (http://www.ckdbiomarkersconsortium.org/), a multidisciplinary, collaborative study group located at over a dozen academic medical centers. The main objective of the consortium was to evaluate new biomarkers for purposes related to CKD in established prospective cohorts, including those enriched for CKD. During the first 5 years of the consortium, many insights into collaborative biomarker research were gained that may be useful to other investigators involved in biomarkers research. These lessons learned are outlined in this Special Feature and include a wide range of issues related to biospecimen collection, storage, and retrieval, and the internal and external quality assessment of laboratories that performed the assays. The authors propose that investigations involving biomarker discovery and validation are greatly enhanced by establishing and following explicit quality control metrics, including the use of blind replicate and proficiency samples, by carefully considering the conditions under which specimens are collected, handled, and stored, and by conducting pilot and feasibility studies when there are concerns about the condition of the specimens or the accuracy or reproducibility of the assays.

AB - Significant advances are needed to improve the diagnosis, prognosis, and management of persons with CKD. Discovery of new biomarkers and improvements in currently available biomarkers for CKD hold great promise to achieve these necessary advances. Interest in identification and evaluation of biomarkers for CKD has increased substantially over the past decade. In 2009, the National Institute of Diabetes and Digestive and Kidney Diseases established the CKD Biomarkers Consortium (http://www.ckdbiomarkersconsortium.org/), a multidisciplinary, collaborative study group located at over a dozen academic medical centers. The main objective of the consortium was to evaluate new biomarkers for purposes related to CKD in established prospective cohorts, including those enriched for CKD. During the first 5 years of the consortium, many insights into collaborative biomarker research were gained that may be useful to other investigators involved in biomarkers research. These lessons learned are outlined in this Special Feature and include a wide range of issues related to biospecimen collection, storage, and retrieval, and the internal and external quality assessment of laboratories that performed the assays. The authors propose that investigations involving biomarker discovery and validation are greatly enhanced by establishing and following explicit quality control metrics, including the use of blind replicate and proficiency samples, by carefully considering the conditions under which specimens are collected, handled, and stored, and by conducting pilot and feasibility studies when there are concerns about the condition of the specimens or the accuracy or reproducibility of the assays.

UR - http://www.scopus.com/inward/record.url?scp=84929159515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929159515&partnerID=8YFLogxK

U2 - 10.2215/CJN.11541114

DO - 10.2215/CJN.11541114

M3 - Article

VL - 10

SP - 894

EP - 902

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 5

ER -